Novartis India (NSE:NOVARTIND) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NOVARTIND Novartis India Ltd NSE:NOVARTIND
69 GF Score
Price ₹1,486.30
GF Value ₹1,040.75
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Novartis India 5-Year Yield-on-Cost %?

Novartis India NSE:NOVARTIND -1.06% 69 5-Year Yield-on-Cost % is 0.00 as of Aug. 26, 2026. GuruFocus rates NSE:NOVARTIND with a GF Score™ of 69/100 and a GF Value™ of ₹1,040.75 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 506 Drug Manufacturers companies, Novartis India ranks better than 72.33% on this metric.

Novartis India's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Novartis India's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Novartis India's highest Yield on Cost was 9.38. The lowest was 0.00. And the median was 4.36.


NSE:NOVARTIND's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.36
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Novartis India  (NSE:NOVARTIND) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Novartis India 5-Year Yield-on-Cost % Related Terms


NSE:NOVARTIND vs ZTS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis India 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis India's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Novartis India's 5-Year Yield-on-Cost % falls into.


NSE:NOVARTIND
69GF Score
Novartis India Ltd NSE:NOVARTIND
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis India 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Novartis India is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Novartis India (NSE:NOVARTIND) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Novartis India and its competitors. According to the industry distribution chart, Novartis India ranks #140 out of 506 companies in the Drug Manufacturers industry, placing it in the top 27.7%.
Is Novartis India's 5-Year Yield-on-Cost % too high?
Novartis India's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Novartis India ranks #140 out of 506 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novartis India has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #140 out of 506 companies for 5-Year Yield-on-Cost %. This puts Novartis India in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (NSE:NOVARTIND) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,040.75, compared to a current price of ₹1,486.30 — trading 42.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Novartis India's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Novartis India (NSE:NOVARTIND), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,486.30 is trading 42.8% above its estimated GF Value™ of ₹1,040.75. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for NSE:NOVARTIND:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: ₹1,040.75 vs. price of ₹1,486.30 (42.8% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis India Business Description

Other Exchanges 500672:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
69GF Score

Get the complete analysis for NSE:NOVARTIND

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,486.30
Price
₹1,040.75
GF Value